What is it about?
Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event-free survival of 70–75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.
Featured Image
Why is it important?
Second allogeneic HSCT from same donor for pediatric APML patient.
Read the Original
This page is a summary of: Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient, Pediatric Transplantation, February 2016, Wiley,
DOI: 10.1111/petr.12677.
You can read the full text:
Contributors
The following have contributed to this page
